GRI Bio Shares Are Trading Lower. The Company Announced That the FDA Has Granted Orphan Drug Designation to GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis.
GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis
GRI Bio (GRI) Gets a Buy From Ascendiant
Dell Technologies To Gain Nearly 79%? Here Are 10 Analyst Calls Investors Should Know
Ascendiant Capital Maintains Buy on GRI Bio, Lowers Price Target to $32
Express News | Green Bio passed the GEM IPO review
Express News | Green Bio's IPO on the ChiNext Board is scheduled for review on May 28.
GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase
Grainger (GRI) Gets a Buy From Deutsche Bank
Jefferies Sticks to Its Buy Rating for Grainger (GRI)
GRI Bio Reports Q1 Results
GRI Bio Highlights Promising Phase 2a IPF Data, Outlook
GRI Bio Q1 EPS $(1.61) Misses $(0.91) Estimate
GRI Bio | 8-K: GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline
Analysts' Top Healthcare Picks: GRI Bio (GRI), Ovid Therapeutics (OVID)
H.C. Wainwright Maintains GRI Bio(GRI.US) With Buy Rating, Maintains Target Price $10
GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline
GRI Bio | 10-Q: Quarterly report
Cohen & Steers Announces Changes to Realty Indexes
Express News | GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse Nkt Cell Agonists for the Treatment of Inflammatory Conditions